基碳化合物受体:治疗性免疫调节的康复目标
Carolina M Polonio1, Kimberly A McHale2, David H Sherr3
1Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
基碳化合物受体 (AHR) 调节免疫反应,是治疗点. 激活AHR的药物显示出治疗炎症性疾病,癌症和感染的前景.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 基碳化合物受体 (AHR) 最初被认为可以调解环境污染物的毒性影响.
- 最近的发现强调了AHR在调节先天性和适应性免疫反应方面的关键作用.
研究的目的:
- 审查AHR在免疫调节中的作用的分子机制.
- 讨论AHR对自身免疫,癌症和感染等疾病的参与.
- 在临床试验中探索针对AHR的治疗方法.
主要方法:
- 关于AHR功能和治疗应用的文献综述.
- 对AHR介导免疫调节的基础分子机制的分析.
- 针对AHR向药物的临床试验数据的摘要.
主要成果:
- AHR激活会影响先天性和适应性免疫.
- 饮食,肠道微生物群和新陈代谢调节AHR活动.
- AHR是治疗免疫相关疾病的可行目标.
结论:
- AHR代表了免疫调节的重要治疗标.
- AHR激活药物,如tapinarof,正在成为各种疾病的治疗方法.
- 对AHR途径的进一步研究有可能为新型免疫疗法提供潜力.
更多相关视频
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
